These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 17583259)

  • 1. Was Part D a giveaway to the pharmaceutical industry?
    Newhouse JP; Seiguer E; Frank RG
    Inquiry; 2007; 44(1):15-25. PubMed ID: 17583259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prescription drug prices in Canada.
    Gross D
    Issue Brief (Public Policy Inst (Am Assoc Retired Pers)); 2003 Jun; (IB62):1-22. PubMed ID: 12807123
    [No Abstract]   [Full Text] [Related]  

  • 3. If foreign drug prices go up, will U.S. prices come down?
    Med Health; 2003 Dec; 57(45):2-4. PubMed ID: 14723168
    [No Abstract]   [Full Text] [Related]  

  • 4. The need for health care reform.
    Mossinghoff GJ
    Health Syst Rev; 1994; 27(3):5-6. PubMed ID: 10134516
    [No Abstract]   [Full Text] [Related]  

  • 5. Reference Pricing in Germany: Implications for U.S. Pharmaceutical Purchasing.
    Robinson JC; Panteli D; Ex P
    Issue Brief (Commonw Fund); 2019 Feb; 2019():1-8. PubMed ID: 30883061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medicare Part D: decision, decisions, decisions. Medicare prescription drug coverage should save many people some money, but it puts a new burden on beneficiaries to be smart shoppers.
    Harv Health Lett; 2005 Dec; 31(2):4-5. PubMed ID: 16440454
    [No Abstract]   [Full Text] [Related]  

  • 7. How insurers' bargaining power affects drug prices in Medicare Part D.
    Natl Bur Econ Res Bull Aging Health; 2009; (4):1-2. PubMed ID: 20355274
    [No Abstract]   [Full Text] [Related]  

  • 8. Affordable prescription drugs--state and federal action.
    Ohio Nurses Rev; 2003 Aug; 78(7):4. PubMed ID: 15134064
    [No Abstract]   [Full Text] [Related]  

  • 9. Part "D" for "defective"--the Medicare drug-benefit chaos.
    Avorn J
    N Engl J Med; 2006 Mar; 354(13):1339-41. PubMed ID: 16571877
    [No Abstract]   [Full Text] [Related]  

  • 10. Medicare program; Medicare prescription drug discount card. Interim final rule with comment period.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2003 Dec; 68(240):69839-927. PubMed ID: 14674398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perverse incentives in the Medicare prescription drug benefit.
    McAdams D; Schwarz M
    Inquiry; 2007; 44(2):157-66. PubMed ID: 17850042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specialty Drugs - A Distinctly American Phenomenon.
    Naci H; Kesselheim AS
    N Engl J Med; 2020 Jun; 382(23):2179-2181. PubMed ID: 32492301
    [No Abstract]   [Full Text] [Related]  

  • 13. Molecular medicine, the Medicare drug benefit, and the need for cost control.
    Gillick MR
    J Am Geriatr Soc; 2006 Sep; 54(9):1442-6. PubMed ID: 16970656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic grand rounds: potential effects of the new medicare drug benefit on pricing for psychotropic medications.
    Huskamp HA; Shinogle JA
    Psychiatr Serv; 2005 Sep; 56(9):1056-8. PubMed ID: 16148317
    [No Abstract]   [Full Text] [Related]  

  • 15. How beneficiaries fare under the new Medicare drug bill.
    Moon M
    Issue Brief (Commonw Fund); 2004 Jun; (730):1-16. PubMed ID: 15176395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multidimensional framework for specialty drug management.
    Bell GK; Baumann SA
    Manag Care; 2013 Mar; 22(3):30-5. PubMed ID: 23610804
    [No Abstract]   [Full Text] [Related]  

  • 17. The new medicare drug benefit: formularies and their potential effects on access to medications.
    Huskamp HA; Keating NL
    J Gen Intern Med; 2005 Jul; 20(7):662-5. PubMed ID: 16050866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medicare prescription drugs: making the new program work.
    Jaffe J
    EBRI Issue Brief; 2004 Jun; (270):1-14. PubMed ID: 15218820
    [No Abstract]   [Full Text] [Related]  

  • 19. Opportunities and challenges of specialty pharmaceuticals.
    Navarro RP; Johnson KA
    J Manag Care Pharm; 2013; 19(1):70-1. PubMed ID: 23383702
    [No Abstract]   [Full Text] [Related]  

  • 20. Medicare risk programs and pharmacy benefits managers.
    Herzfeld J
    Med Interface; 1996 Dec; 9(12):75-8. PubMed ID: 10172875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.